Curis, Inc. Logo

Curis, Inc.

CRIS

(1.0)
Stock Price

5,86 USD

-59.35% ROA

-169.22% ROE

-1.55x PER

Market Cap.

76.682.111,00 USD

14.72% DER

0% Yield

-473.04% NPM

Curis, Inc. Stock Analysis

Curis, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Curis, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (10%), which means it has a small amount of debt compared to the ownership it holds

2 PBV

The stock's PBV ratio (1.42x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

3 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

4 ROE

Negative ROE (-138.38%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-59.35%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-1) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Curis, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Curis, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Buy
4 Stoch RSI Sell

Curis, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Curis, Inc. Revenue
Year Revenue Growth
1999 3.211.860
2000 997.078 -222.13%
2001 1.086.503 8.23%
2002 18.390.538 94.09%
2003 11.048.233 -66.46%
2004 4.952.615 -123.08%
2005 6.002.446 17.49%
2006 14.935.637 59.81%
2007 16.388.554 8.87%
2008 8.366.617 -95.88%
2009 8.589.940 2.6%
2010 15.999.565 46.31%
2011 14.762.580 -8.38%
2012 16.971.991 13.02%
2013 15.002.032 -13.13%
2014 9.843.481 -52.41%
2015 7.878.407 -24.94%
2016 7.527.000 -4.67%
2017 9.898.000 23.95%
2018 10.428.000 5.08%
2019 10.004.000 -4.24%
2020 10.835.000 7.67%
2021 10.649.000 -1.75%
2022 10.162.000 -4.79%
2023 11.332.000 10.32%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Curis, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1999 10.434.560
2000 17.423.895 40.11%
2001 29.072.068 40.07%
2002 14.057.715 -106.81%
2003 13.399.492 -4.91%
2004 11.569.749 -15.81%
2005 13.705.074 15.58%
2006 14.589.647 6.06%
2007 14.779.184 1.28%
2008 13.226.449 -11.74%
2009 9.932.768 -33.16%
2010 11.372.850 12.66%
2011 13.692.659 16.94%
2012 15.492.302 11.62%
2013 12.926.834 -19.85%
2014 13.659.398 5.36%
2015 26.699.370 48.84%
2016 31.590.000 15.48%
2017 33.344.000 5.26%
2018 24.413.000 -36.58%
2019 22.302.000 -9.47%
2020 23.068.000 3.32%
2021 34.884.000 33.87%
2022 43.277.000 19.39%
2023 41.520.000 -4.23%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Curis, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1999 5.524.077
2000 25.958.474 78.72%
2001 20.850.827 -24.5%
2002 10.319.606 -102.05%
2003 7.485.667 -37.86%
2004 8.932.467 16.2%
2005 8.089.738 -10.42%
2006 10.373.883 22.02%
2007 9.983.931 -3.91%
2008 8.259.812 -20.87%
2009 8.702.082 5.08%
2010 10.264.459 15.22%
2011 8.272.424 -24.08%
2012 10.423.014 20.63%
2013 11.293.811 7.71%
2014 11.706.754 3.53%
2015 12.906.334 9.29%
2016 15.588.000 17.2%
2017 25.818.000 39.62%
2018 14.785.000 -74.62%
2019 11.555.000 -27.95%
2020 12.131.000 4.75%
2021 17.297.000 29.87%
2022 19.648.000 11.97%
2023 19.044.000 -3.17%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Curis, Inc. EBITDA
Year EBITDA Growth
1999 -12.886.782
2000 278.147.535 104.63%
2001 -47.242.010 688.77%
2002 -19.949.396 -136.81%
2003 -6.966.029 -186.38%
2004 -16.140.542 56.84%
2005 -14.977.705 -7.76%
2006 -8.465.149 -76.93%
2007 -6.958.815 -21.65%
2008 -12.131.185 42.64%
2009 -10.267.219 -18.15%
2010 -6.840.178 -50.1%
2011 -4.546.111 -50.46%
2012 380.193 1295.74%
2013 -9.251.759 104.11%
2014 -15.697.146 41.06%
2015 -31.308.199 49.86%
2016 -39.645.000 21.03%
2017 -49.116.000 19.28%
2018 -28.649.000 -71.44%
2019 -23.800.000 -20.37%
2020 -24.813.000 4.08%
2021 -40.964.000 39.43%
2022 -53.020.000 22.74%
2023 -49.472.000 -7.17%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Curis, Inc. Gross Profit
Year Gross Profit Growth
1999 3.211.860
2000 12.145.188 73.55%
2001 1.086.503 -1017.82%
2002 -5.318.395.462 100.02%
2003 11.048.233 48237.97%
2004 4.952.615 -123.08%
2005 6.002.446 17.49%
2006 14.935.637 59.81%
2007 16.388.554 8.87%
2008 8.366.617 -95.88%
2009 8.589.940 2.6%
2010 15.999.565 46.31%
2011 14.762.580 -8.38%
2012 16.795.509 12.1%
2013 14.804.236 -13.45%
2014 9.503.903 -55.77%
2015 7.472.651 -27.18%
2016 7.128.000 -4.84%
2017 9.402.000 24.19%
2018 9.865.000 4.69%
2019 9.501.000 -3.83%
2020 10.301.000 7.77%
2021 10.116.000 -1.83%
2022 9.905.000 -2.13%
2023 11.092.000 10.7%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Curis, Inc. Net Profit
Year Net Profit Growth
1999 -12.109.790
2000 -350.350.624 96.54%
2001 -81.863.650 -327.97%
2002 -82.315.435 0.55%
2003 -11.623.252 -608.2%
2004 -13.904.274 16.41%
2005 -14.855.172 6.4%
2006 -8.829.322 -68.25%
2007 -6.964.243 -26.78%
2008 -12.123.098 42.55%
2009 -9.822.601 -23.42%
2010 -4.435.310 -121.46%
2011 -9.858.895 55.01%
2012 -16.416.907 39.95%
2013 -12.322.012 -33.23%
2014 -18.728.734 34.21%
2015 -58.981.030 68.25%
2016 -60.411.000 2.37%
2017 -53.317.000 -13.31%
2018 -32.575.000 -63.67%
2019 -36.804.000 11.49%
2020 -34.881.000 -5.51%
2021 -50.640.000 31.12%
2022 -60.324.000 16.05%
2023 -48.724.000 -23.81%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Curis, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1999 -136
2000 -1.980 93.13%
2001 -258 -667.44%
2002 -257 -0.39%
2003 -33 -678.79%
2004 -35 5.71%
2005 -31 -12.9%
2006 -18 -72.22%
2007 -13 -38.46%
2008 -19 31.58%
2009 -15 -26.67%
2010 -6 -150%
2011 -13 53.85%
2012 -21 38.1%
2013 -15 -40%
2014 -22 31.82%
2015 -48 54.17%
2016 -45 -6.67%
2017 -36 -28.57%
2018 -20 -84.21%
2019 -22 13.64%
2020 -14 -57.14%
2021 -11 -27.27%
2022 -13 8.33%
2023 -9 -50%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Curis, Inc. Free Cashflow
Year Free Cashflow Growth
1999 -15.378.014
2000 -25.165.098 38.89%
2001 -26.622.582 5.47%
2002 -7.329.289 -263.24%
2003 -9.912.813 26.06%
2004 -9.246.045 -7.21%
2005 -11.009.929 16.02%
2006 -6.673.722 -64.97%
2007 -8.660.706 22.94%
2008 -12.501.627 30.72%
2009 -7.608.131 -64.32%
2010 -1.903.939 -299.6%
2011 -4.823.702 60.53%
2012 -15.298.280 68.47%
2013 -9.692.586 -57.83%
2014 -16.904.953 42.66%
2015 -29.938.775 43.53%
2016 -36.140.000 17.16%
2017 -48.543.000 25.55%
2018 -30.150.000 -61%
2019 -26.246.000 -14.87%
2020 -26.416.000 0.64%
2021 -37.619.000 29.78%
2022 -54.753.000 31.29%
2023 1.633.000 3452.91%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Curis, Inc. Operating Cashflow
Year Operating Cashflow Growth
1999 -14.768.001
2000 -23.591.604 37.4%
2001 -24.876.633 5.17%
2002 -6.917.598 -259.61%
2003 -9.760.756 29.13%
2004 -7.329.388 -33.17%
2005 -8.139.292 9.95%
2006 -5.979.611 -36.12%
2007 -8.594.237 30.42%
2008 -12.441.081 30.92%
2009 -7.588.594 -63.94%
2010 -1.629.099 -365.82%
2011 -4.563.297 64.3%
2012 -15.193.305 69.97%
2013 -9.539.577 -59.27%
2014 -16.812.744 43.26%
2015 -29.890.790 43.75%
2016 -35.811.000 16.53%
2017 -48.355.000 25.94%
2018 -30.065.000 -60.83%
2019 -26.205.000 -14.73%
2020 -25.739.000 -1.81%
2021 -37.619.000 31.58%
2022 -54.337.000 30.77%
2023 1.633.000 3427.43%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Curis, Inc. Capital Expenditure
Year Capital Expenditure Growth
1999 610.013
2000 1.573.494 61.23%
2001 1.745.949 9.88%
2002 411.691 -324.09%
2003 152.057 -170.75%
2004 1.916.657 92.07%
2005 2.870.637 33.23%
2006 694.111 -313.57%
2007 66.469 -944.26%
2008 60.546 -9.78%
2009 19.537 -209.9%
2010 274.840 92.89%
2011 260.405 -5.54%
2012 104.975 -148.06%
2013 153.009 31.39%
2014 92.209 -65.94%
2015 47.985 -92.16%
2016 329.000 85.41%
2017 188.000 -75%
2018 85.000 -121.18%
2019 41.000 -107.32%
2020 677.000 93.94%
2021 0 0%
2022 416.000 100%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Curis, Inc. Equity
Year Equity Growth
1999 23.421.586
2000 168.813.766 86.13%
2001 101.019.646 -67.11%
2002 18.542.379 -444.8%
2003 38.865.213 52.29%
2004 48.909.295 20.54%
2005 37.999.579 -28.71%
2006 35.897.139 -5.86%
2007 46.844.563 23.37%
2008 37.224.596 -25.84%
2009 33.052.258 -12.62%
2010 45.517.657 27.39%
2011 39.875.957 -14.15%
2012 34.267.498 -16.37%
2013 45.173.585 24.14%
2014 29.783.626 -51.67%
2015 64.510.478 53.83%
2016 29.266.000 -120.43%
2017 23.993.000 -21.98%
2018 -4.496.000 633.65%
2019 -33.911.000 86.74%
2020 130.670.000 125.95%
2021 90.707.000 -44.06%
2022 46.552.000 -94.85%
2023 29.591.000 -57.32%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Curis, Inc. Assets
Year Assets Growth
1999 28.892.291
2000 182.681.990 84.18%
2001 144.756.217 -26.2%
2002 62.441.693 -131.83%
2003 55.736.490 -12.03%
2004 67.634.813 17.59%
2005 60.914.253 -11.03%
2006 52.268.253 -16.54%
2007 53.816.685 2.88%
2008 39.981.872 -34.6%
2009 36.099.249 -10.76%
2010 50.649.143 28.73%
2011 48.180.065 -5.12%
2012 69.980.408 31.15%
2013 80.590.808 13.17%
2014 62.613.569 -28.71%
2015 94.965.139 34.07%
2016 57.752.000 -64.44%
2017 73.798.000 21.74%
2018 37.365.000 -97.51%
2019 35.107.000 -6.43%
2020 204.358.000 82.82%
2021 162.301.000 -25.91%
2022 108.848.000 -49.11%
2023 89.975.000 -20.98%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Curis, Inc. Liabilities
Year Liabilities Growth
1999 5.470.705
2000 13.868.224 60.55%
2001 43.736.571 68.29%
2002 43.899.314 0.37%
2003 16.871.277 -160.2%
2004 18.725.518 9.9%
2005 22.914.674 18.28%
2006 16.371.114 -39.97%
2007 6.972.122 -134.81%
2008 2.757.276 -152.86%
2009 3.046.991 9.51%
2010 5.131.486 40.62%
2011 8.304.108 38.21%
2012 35.712.910 76.75%
2013 35.417.223 -0.83%
2014 32.829.943 -7.88%
2015 30.454.661 -7.8%
2016 28.486.000 -6.91%
2017 49.805.000 42.8%
2018 41.861.000 -18.98%
2019 69.018.000 39.35%
2020 73.688.000 6.34%
2021 71.594.000 -2.92%
2022 62.296.000 -14.93%
2023 60.384.000 -3.17%

Curis, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.79
Net Income per Share
-8.4
Price to Earning Ratio
-1.55x
Price To Sales Ratio
7.51x
POCF Ratio
-2.42
PFCF Ratio
-2.5
Price to Book Ratio
2.52
EV to Sales
5.41
EV Over EBITDA
-1.22
EV to Operating CashFlow
-1.8
EV to FreeCashFlow
-1.8
Earnings Yield
-0.65
FreeCashFlow Yield
-0.4
Market Cap
0,08 Bil.
Enterprise Value
0,06 Bil.
Graham Number
31.27
Graham NetNet
1.84

Income Statement Metrics

Net Income per Share
-8.4
Income Quality
0.88
ROE
-1.38
Return On Assets
-0.61
Return On Capital Employed
-0.76
Net Income per EBT
1
EBT Per Ebit
0.98
Ebit per Revenue
-4.82
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
1.77
Research & Developement to Revenue
3.74
Stock Based Compensation to Revenue
0.61
Gross Profit Margin
0.97
Operating Profit Margin
-4.82
Pretax Profit Margin
-4.73
Net Profit Margin
-4.73

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-5.37
Free CashFlow per Share
-5.37
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-1.3
Return on Tangible Assets
-0.59
Days Sales Outstanding
101.77
Days Payables Outstanding
8321.68
Days of Inventory on Hand
867.07
Receivables Turnover
3.59
Payables Turnover
0.04
Inventory Turnover
0.42
Capex per Share
0

Balance Sheet

Cash per Share
11,97
Book Value per Share
5,17
Tangible Book Value per Share
3.6
Shareholders Equity per Share
5.17
Interest Debt per Share
1.15
Debt to Equity
0.15
Debt to Assets
0.05
Net Debt to EBITDA
0.47
Current Ratio
6.19
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
0.15
Working Capital
0,06 Bil.
Intangibles to Total Assets
0.1
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
272000
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Curis, Inc. Dividends
Year Dividends Growth

Curis, Inc. Profile

About Curis, Inc.

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

CEO
Mr. James E. Dentzer
Employee
49
Address
Building C
Lexington, 02421

Curis, Inc. Executives & BODs

Curis, Inc. Executives & BODs
# Name Age
1 Ms. Diantha Duvall CPA, M.B.A.
Chief Financial Officer and Principal Financial & Accounting Officer
70
2 Ms. Elif McDonald
Vice President of Investor Relations & Corporate Communications
70
3 Dr. Jonathan B. Zung Ph.D.
Chief Development Officer
70
4 Mr. James E. Dentzer
President, Chief Executive Officer, Secretary, Treasurer & Director
70
5 Dr. Reinhard Wilhelm von Roemeling M.D.
Senior Vice President of Clinical Development
70
6 Mr. Mark W. Noel
Vice President of Technology Management & Intellectual Property
70

Curis, Inc. Competitors